Høst Arne, Halken Susanne, Jacobsen Hans P, Christensen Anne E, Herskind Anne M, Plesner Karin
Department of Pediatrics, Odense University Hospital, Odense, Denmark.
Pediatr Allergy Immunol. 2002;13(s15):23-8. doi: 10.1034/j.1399-3038.13.s.15.7.x.
A cohort of 1,749 newborns from the municipality of Odense, born during 1995 at the Odense University Hospital, were followed up prospectively for the development of cow's milk protein allergy/intolerance (CMPA/I) during the first year of life. Once a diagnosis of CMPA/I was confirmed, a milk-free diet was continued until a new milk challenge had shown development of tolerance. All infants with CMPA/I were rechallenged at 12 months of age and, in the event of continued clinical sensitivity to cow's milk protein, controlled rechallenges were performed every 6 months up to 3 years of age; and thereafter every 12 months until the age of 15 years. From the same birth cohort, 276 infants were randomly selected at birth for prospective non-interventional follow-up in order to investigate the natural course of sensitization and development of atopic disease during childhood. Standardized questionnaires on atopic heredity, environmental factors and presence of atopic symptoms were answered at 0, 6, 12 and 18 months and at 5, 10 and 15 years of age. Interviews on atopic history and environmental factors as well as physical examination were carried out at 18 months, 5, 10 and 15 years of age. Skin prick test and specific sIgE (Pharmacia CAP) testing were performed at 18 months, 5, 10 and 15 years of age against a panel of inhalant allergens (birch, grass, mugwort, dog, cat, horse, Dermatophagoidespteronyssinus, Dermatophagoides farinae, alternaria and cladosporium herbarum). Furthermore, lung function measurements were performed in children when 10 and 15 years of age. Based on controlled milk elimination and challenge procedures, the diagnosis of CMPA/I was confirmed in 39 out of 117 infants, with symptoms suggestive of CMPA/I, thus resulting in a 1-year incidence of CMPA/I of 2.2%. The overall prognosis of CMPA/I was good, with a total recovery of 56% at 1 year, 77% at 2 years, 87% at 3 years, 92% at 5 and 10 years and 97% at 15 years of age. In children younger than 10 years of age, 41% developed asthma and 31% rhinoconjunctivitis. Children with non-IgE-mediated CMPI had a good prognosis, whereas children with IgE-mediated CMPA in early childhood had a significantly increased risk for persistent CMPA, development of other food allergies, asthma and rhinoconjunctivitis. During early infancy, recurrent wheezing was the most prevalent disease (20%), followed by atopic dermatitis (14%) and food allergy (7%) at 18 months of age. Physician diagnosed asthma increased from 2% at 1.5 years of age to 9% at 10 years of age. Rhinoconjunctivitis increased from <1% at 1.5 years of age to 9% at 10 years of age. Overall, the current prevalence of any atopic disease was 20% at 1.5 years of age, declining to 14% at 5 years of age and followed by an increase to 25% at 10 years of age. Sensitization to inhalant and/or food allergens (specific IgE of > or = class 2; CAP RAST) showed a low rate of sensitization among asymptomatics (3%, 10% and 12%) compared with higher rates of sensitization of 8%, 39% and 30% among symptomatic atopics at 1.5, 5 and 10 years of age respectively. The highest rate of sensitization (53%) was found among children with current asthma at 10 years of age.
1995年在欧登塞市出生于欧登塞大学医院的1749名新生儿组成的队列,在出生后的第一年接受前瞻性随访,以观察牛奶蛋白过敏/不耐受(CMPA/I)的发展情况。一旦确诊CMPA/I,就持续采用无奶饮食,直到新的牛奶激发试验显示出耐受性发展。所有患有CMPA/I的婴儿在12个月大时进行再次激发试验,如果对牛奶蛋白仍有临床敏感性,则在3岁之前每6个月进行一次对照激发试验;此后每12个月进行一次,直至15岁。从同一出生队列中,随机选取276名婴儿在出生时进行前瞻性非干预性随访,以研究儿童期致敏和特应性疾病的自然病程。在0、6、12和18个月以及5、10和15岁时回答关于特应性遗传、环境因素和特应性症状的标准化问卷。在18个月、5、10和15岁时进行关于特应性病史和环境因素的访谈以及体格检查。在18个月、5、10和15岁时针对一组吸入性变应原(桦树、草、艾蒿、狗、猫、马、屋尘螨、粉尘螨、链格孢和枝孢)进行皮肤点刺试验和特异性sIgE(Pharmacia CAP)检测。此外,在10岁和15岁的儿童中进行肺功能测量。基于对照的牛奶排除和激发程序,在117名有CMPA/I症状提示的婴儿中,确诊39例CMPA/I,因此CMPA/I的1年发病率为2.2%*。CMPA/I的总体预后良好,1岁时总恢复率为56%,2岁时为77%,3岁时为87%,5岁和10岁时为92%,15岁时为97%。在10岁以下的儿童中,41%患哮喘,31%患鼻结膜炎。非IgE介导的CMPI儿童预后良好,而幼儿期IgE介导的CMPA儿童持续CMPA、发生其他食物过敏、哮喘和鼻结膜炎的风险显著增加。在婴儿早期,反复喘息是最常见的疾病(20%),其次是18个月时特应性皮炎(14%)和食物过敏(7%)。医生诊断的哮喘从1.5岁时的2%增加到10岁时的9%。鼻结膜炎从1.5岁时的<1%增加到10岁时的9%。总体而言,任何特应性疾病的当前患病率在1.5岁时为20%,5岁时降至14%,随后在10岁时增至25%。与无症状者中较低的致敏率(3%、10%和12%)相比,有症状的特应性患者在1.5、5和10岁时的致敏率较高,分别为8%、39%和30%。在10岁时患有当前哮喘的儿童中发现最高的致敏率(53%)。
*注:原文中“thus resulting in a 1-year incidence of CMPA/I of 2.2%”这里的2.2%的计算逻辑不太清晰,按照字面翻译为“因此CMPA/I的1年发病率为2.2%”,可能存在数据来源或计算过程未详细说明的情况。